Media Releases

Roche Diagnostics launches its new blood gas analyzer

High quality test results to make fast and reliable medical decisions in critical situations

Roche Diagnostics announced today the introduction of  its new blood gas analyzer, the cobas b 123 blood gas system, in Canada.

 

The award winning cobas b 123 blood gas system is a fast, multi-parameter analyzer, delivering many of the vital results that physicians need in order to make timely decisions in critical situations. From one drop of blood the system can assess a patient’s oxygenation and acid/base status as well as deliver important information on electrolytes and the metabolites glucose and lactate within 2 minutes.

 

Roche has designed the easy-to-use and nearly maintenance free system in order to meet the needs of a broad range of clinical settings where high quality results for immediate medical decisions and treatment adjustments are needed.

 

“Roche Diagnostics is very pleased to bring the cobas b 123 blood gas system to Canada,” said Christopher Parker, President and General Manager,  Roche Diagnostics. “Roche has designed this compact, easy-to-use cobas b 123 blood gas system in order to meet the needs of a broad range of clinical settings, where high quality results for immediate medical decisions and treatment adjustments are needed. It is the ideal choice for any laboratory.”

  

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

 

All trademarks used or mentioned in this release are protected by law.

 

For further information:

 

Michèle Beaubien

Roche Diagniostics Canada

(450) 686-5500

Michele.beaubien@roche.com

Prev                                                           Back to list                                                       Next